Question 1

What specific safety concerns are being monitored in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration clinical trial (NCT01678872). Contact the study team or your healthcare provider for specific answers.

Question 2

How often will I need to visit the study site for follow-up?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration clinical trial (NCT01678872). Contact the study team or your healthcare provider for specific answers.

Question 3

What should I expect during the follow-up visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration clinical trial (NCT01678872). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration clinical trial (NCT01678872). Contact the study team or your healthcare provider for specific answers.

Question 5

How will this study impact my current treatment plan for AMD?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration clinical trial (NCT01678872). Contact the study team or your healthcare provider for specific answers.

What this study is about